Diabetes mellitus and antipsychotic treatment in the United Kingdom

Christopher Carlson, Kenneth Hornbuckle, Frank DeLisle, Ludmila Kryzhanovskaya, Alan Breier, Patrizia Cavazzoni

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Objective: Treatment-emergent diabetes has been reported during exposure to conventional and atypical antipsychotics. This retrospective cohort study explored the UK General Practice Research Database (GPRD) to determine hazard ratios of diabetes for patients prescribed antipsychotics. Methods: A Cox proportional hazard regression model using age, gender, and obesity (BMI > 30 kg/m2) was used to determine the hazard ratio (HR) of diabetes development in conventional antipsychotic (N = 59,089), atypical antipsychotic (N = 9053), individual antipsychotic, and general patient population cohorts (N = 1,491,548). Results: Compared with the general GPRD patient population, patients exposed to conventional or atypical antipsychotics had a higher risk of developing diabetes (atypical antipsychotic cohort: HR = 2.9, CI = 2.0-4.4; and conventional antipsychotic cohort: HR = 1.9, CI = 1.6-2.3). The risk of developing diabetes during thioridazine, risperidone, or olanzapine treatment was significantly higher compared with the general GPRD patient population. Conclusion: Consistent with other epidemiology studies, this study supports an increased risk of developing diabetes during treatment with antipsychotics.

Original languageEnglish (US)
Pages (from-to)366-375
Number of pages10
JournalEuropean Neuropsychopharmacology
Volume16
Issue number5
DOIs
StatePublished - Jul 2006

Fingerprint

Antipsychotic Agents
Diabetes Mellitus
General Practice
Therapeutics
Databases
olanzapine
Research
Population
Thioridazine
United Kingdom
Risperidone
Proportional Hazards Models
Epidemiology
Cohort Studies
Retrospective Studies
Obesity

Keywords

  • Antipsychotics
  • Diabetes
  • Epidemiology

ASJC Scopus subject areas

  • Clinical Neurology
  • Psychiatry and Mental health
  • Biological Psychiatry
  • Neurology
  • Pharmacology
  • Psychology(all)

Cite this

Carlson, C., Hornbuckle, K., DeLisle, F., Kryzhanovskaya, L., Breier, A., & Cavazzoni, P. (2006). Diabetes mellitus and antipsychotic treatment in the United Kingdom. European Neuropsychopharmacology, 16(5), 366-375. https://doi.org/10.1016/j.euroneuro.2005.11.002

Diabetes mellitus and antipsychotic treatment in the United Kingdom. / Carlson, Christopher; Hornbuckle, Kenneth; DeLisle, Frank; Kryzhanovskaya, Ludmila; Breier, Alan; Cavazzoni, Patrizia.

In: European Neuropsychopharmacology, Vol. 16, No. 5, 07.2006, p. 366-375.

Research output: Contribution to journalArticle

Carlson, C, Hornbuckle, K, DeLisle, F, Kryzhanovskaya, L, Breier, A & Cavazzoni, P 2006, 'Diabetes mellitus and antipsychotic treatment in the United Kingdom', European Neuropsychopharmacology, vol. 16, no. 5, pp. 366-375. https://doi.org/10.1016/j.euroneuro.2005.11.002
Carlson, Christopher ; Hornbuckle, Kenneth ; DeLisle, Frank ; Kryzhanovskaya, Ludmila ; Breier, Alan ; Cavazzoni, Patrizia. / Diabetes mellitus and antipsychotic treatment in the United Kingdom. In: European Neuropsychopharmacology. 2006 ; Vol. 16, No. 5. pp. 366-375.
@article{fb0edaf86a5e421ca6a9837060a4b02b,
title = "Diabetes mellitus and antipsychotic treatment in the United Kingdom",
abstract = "Objective: Treatment-emergent diabetes has been reported during exposure to conventional and atypical antipsychotics. This retrospective cohort study explored the UK General Practice Research Database (GPRD) to determine hazard ratios of diabetes for patients prescribed antipsychotics. Methods: A Cox proportional hazard regression model using age, gender, and obesity (BMI > 30 kg/m2) was used to determine the hazard ratio (HR) of diabetes development in conventional antipsychotic (N = 59,089), atypical antipsychotic (N = 9053), individual antipsychotic, and general patient population cohorts (N = 1,491,548). Results: Compared with the general GPRD patient population, patients exposed to conventional or atypical antipsychotics had a higher risk of developing diabetes (atypical antipsychotic cohort: HR = 2.9, CI = 2.0-4.4; and conventional antipsychotic cohort: HR = 1.9, CI = 1.6-2.3). The risk of developing diabetes during thioridazine, risperidone, or olanzapine treatment was significantly higher compared with the general GPRD patient population. Conclusion: Consistent with other epidemiology studies, this study supports an increased risk of developing diabetes during treatment with antipsychotics.",
keywords = "Antipsychotics, Diabetes, Epidemiology",
author = "Christopher Carlson and Kenneth Hornbuckle and Frank DeLisle and Ludmila Kryzhanovskaya and Alan Breier and Patrizia Cavazzoni",
year = "2006",
month = "7",
doi = "10.1016/j.euroneuro.2005.11.002",
language = "English (US)",
volume = "16",
pages = "366--375",
journal = "European Neuropsychopharmacology",
issn = "0924-977X",
publisher = "Elsevier",
number = "5",

}

TY - JOUR

T1 - Diabetes mellitus and antipsychotic treatment in the United Kingdom

AU - Carlson, Christopher

AU - Hornbuckle, Kenneth

AU - DeLisle, Frank

AU - Kryzhanovskaya, Ludmila

AU - Breier, Alan

AU - Cavazzoni, Patrizia

PY - 2006/7

Y1 - 2006/7

N2 - Objective: Treatment-emergent diabetes has been reported during exposure to conventional and atypical antipsychotics. This retrospective cohort study explored the UK General Practice Research Database (GPRD) to determine hazard ratios of diabetes for patients prescribed antipsychotics. Methods: A Cox proportional hazard regression model using age, gender, and obesity (BMI > 30 kg/m2) was used to determine the hazard ratio (HR) of diabetes development in conventional antipsychotic (N = 59,089), atypical antipsychotic (N = 9053), individual antipsychotic, and general patient population cohorts (N = 1,491,548). Results: Compared with the general GPRD patient population, patients exposed to conventional or atypical antipsychotics had a higher risk of developing diabetes (atypical antipsychotic cohort: HR = 2.9, CI = 2.0-4.4; and conventional antipsychotic cohort: HR = 1.9, CI = 1.6-2.3). The risk of developing diabetes during thioridazine, risperidone, or olanzapine treatment was significantly higher compared with the general GPRD patient population. Conclusion: Consistent with other epidemiology studies, this study supports an increased risk of developing diabetes during treatment with antipsychotics.

AB - Objective: Treatment-emergent diabetes has been reported during exposure to conventional and atypical antipsychotics. This retrospective cohort study explored the UK General Practice Research Database (GPRD) to determine hazard ratios of diabetes for patients prescribed antipsychotics. Methods: A Cox proportional hazard regression model using age, gender, and obesity (BMI > 30 kg/m2) was used to determine the hazard ratio (HR) of diabetes development in conventional antipsychotic (N = 59,089), atypical antipsychotic (N = 9053), individual antipsychotic, and general patient population cohorts (N = 1,491,548). Results: Compared with the general GPRD patient population, patients exposed to conventional or atypical antipsychotics had a higher risk of developing diabetes (atypical antipsychotic cohort: HR = 2.9, CI = 2.0-4.4; and conventional antipsychotic cohort: HR = 1.9, CI = 1.6-2.3). The risk of developing diabetes during thioridazine, risperidone, or olanzapine treatment was significantly higher compared with the general GPRD patient population. Conclusion: Consistent with other epidemiology studies, this study supports an increased risk of developing diabetes during treatment with antipsychotics.

KW - Antipsychotics

KW - Diabetes

KW - Epidemiology

UR - http://www.scopus.com/inward/record.url?scp=33744552439&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33744552439&partnerID=8YFLogxK

U2 - 10.1016/j.euroneuro.2005.11.002

DO - 10.1016/j.euroneuro.2005.11.002

M3 - Article

VL - 16

SP - 366

EP - 375

JO - European Neuropsychopharmacology

JF - European Neuropsychopharmacology

SN - 0924-977X

IS - 5

ER -